Pre-emptive use of low-dose systemic or topical tetracyclines [28,31,32] with topical steroids [29,33] for EGFR inhibitor-induced cutaneous adverse events have been analyzed in randomized open-label trials and a retrospective cohort study showing promising outcomes in reducing the incidence or severity of a rash but not necessarily other side effects, including hair disorders. The gene discussed is EGFR; the disease is disorder of pilosebaceous unit.